Balance Sheet
AssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ainos (AIMD) Cash & Current Investments (2016 - 2026)

Ainos filings provide 16 years of Cash & Current Investments readings, the most recent being $417353.0 for Q4 2025.

  • On a quarterly basis, Cash & Current Investments fell 89.28% to $417353.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $417353.0, a 89.28% decrease, with the full-year FY2025 number at $417353.0, down 89.28% from a year prior.
  • Cash & Current Investments hit $417353.0 in Q4 2025 for Ainos, down from $1.1 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $8.0 million in Q2 2024 to a low of $9377.0 in Q1 2021.
  • Median Cash & Current Investments over the past 5 years was $1.8 million (2021), compared with a mean of $2.1 million.
  • Biggest five-year swings in Cash & Current Investments: tumbled 96.76% in 2021 and later surged 19856.8% in 2022.
  • Ainos' Cash & Current Investments stood at $1.8 million in 2021, then rose by 5.82% to $1.9 million in 2022, then rose by 1.74% to $1.9 million in 2023, then soared by 106.45% to $3.9 million in 2024, then tumbled by 89.28% to $417353.0 in 2025.
  • The last three reported values for Cash & Current Investments were $417353.0 (Q4 2025), $1.1 million (Q3 2025), and $1.2 million (Q2 2025) per Business Quant data.